Inside Prescient Therapeutics’ (ASX:PTX) clinical progress to cancer treatment
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to...
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to...
Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Prescient Therapeutics (ASX: PTX) has presented exciting new data on CellPryme-A at the 7th Annual CAR-TCR...
Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The...
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the...
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key...
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.